CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 427,909	$ 492,860
Marketable securities	4,741	4,941
Prepaid expenses	8,296	5,354
Other current assets	1,313	1,348
Total current assets	442,259	504,503
Property and equipment, net of accumulated depreciation and amortization of $6,260 and $4,316 at June 30, 2019 and December 31, 2018, respectively	35,177	23,469
Other long-term assets	249	68
Total Assets	477,685	528,040
Current Liabilities:
Accounts payable and accrued expenses	38,967	31,722
Liability related to sale of future royalties - current	5,314	0
Lease liability - current	271
Total current liabilities	44,552	31,722
Convertible senior notes, net	7,081	7,055
Liability related to sale of future royalties - non-current	236,354	221,295
Deferred revenues	65,000	0
Other long-term liabilities	10,138	2,119
Total Liabilities	363,125	262,191
Commitments and Contingencies
Stockholders' Equity:
Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at June 30, 2019 and December 31, 2018	0	0
Common stock, $0.01 par value; authorized 250,000,000 shares; issued 191,972,321 shares and outstanding 191,852,700 shares at June 30, 2019; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018	1,920	1,905
Capital contributed in excess of par	1,232,575	1,219,237
Treasury stock, at cost: 119,621 shares at June 30, 2019 and 34,725 shares at December 31, 2018	(2,095)	(824)
Accumulated deficit	(1,116,506)	(953,216)
Accumulated other comprehensive loss	(365)	(351)
Total Immunomedics, Inc. stockholders' equity	115,529	266,751
Noncontrolling interest in subsidiary	(969)	(902)
Total stockholders' equity	114,560	265,849
Total Liabilities and Stockholders' Equity	$ 477,685	$ 528,040